Scholar Rock Holding Corp SRRK
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-05-24 |
| Shares Out. | 119,830,000 |
| Website | scholarrock.com/ ↗ |
| Phone | 13026587581 |
| Employees | 289 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$109.9M |
| Free Cash Flow | -$297.0M |
| Total Assets | $523.5M |
| Total Liabilities | $269.8M |
| Equity | $253.8M |
About Scholar Rock Holding Corp
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corp is a publicly traded company under the ticker symbol SRRK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.